Developments in Brief : New Anti-Cancer Drug Tests Begin on Humans
The first tests in humans of a new genetically engineered anti-cancer agent called tumor necrosis factor, or TNF, were begun by Cetus Corp. of Emeryville, Calif., last week.
TNF is a natural substance produced in small amounts by certain white blood cells called macrophages. It appears to selectively kill some types of cancer cells and certain infectious microorganisms without affecting most normal cells.
For the record:
12:00 a.m. June 19, 1986 For the Record
Los Angeles Times Thursday June 19, 1986 Home Edition Part 1 Page 2 Column 1 Metro Desk 2 inches; 39 words Type of Material: Correction
The Times incorrectly reported Sunday that Cetus Corp. had begun the first clinical trials in humans with an anti-cancer drug called tumor necrosis factor or TNF. Other companies began testing TNF in humans last fall. The Cetus tests are the first trials of an altered form of TNF.
Cetus researchers altered the protein slightly to make it more effective at killing tumor cells. Scientists at Cetus hope it will be especially effective at treating colid or metastatic tumors that are difficult to treat with available therapies.
The initial studies are being conducted by Dr. Robert Kriegel of the Fox Chase Cancer Center in Philadelphia. The Upstate Medical Center in New York and the University of Arizona are also expected to participate in the trials.
